Croma-Pharma GmbH
Croma-Pharma GmbH is an Austrian family-owned company based in Leobendorf, north of Vienna. The company specializes in the industrial production of hyaluronic acid syringes and is one of the world’s leading experts in this field. After selling the ophthalmic and orthopaedic business in 2014, Croma is solely focusing on minimally aesthetic medicine. Croma offers a wide range of state-of-the-art products in minimally invasive aesthetic medicine. The company employs about 450 people worldwide, including Australia, Brazil, Canada, France, Germany, the Netherlands, Poland, Portugal, Romania, Switzerland, Spain and the home country of Austria. In addition, Croma distributes its products in more than 70 countries.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About us
In the 80s, successful active substances to treat glaucoma were licensed.
Subsequently, the company expanded its portfolio in the ophthalmological segment (eye care).
They started selling intraocular lenses (IOL) and producing viscoelastic ampoules to be used for cataract surgery.
Croma was certified as one of the first manufacturers of medicinal products in Austria.
Due to the increasing demand, the company relocated to its newly constructed fully-automated production facility in Leobendorf near Vienna.
This set the milestone for the successful future of the family company.
Over the next two decades, more than 40 million syringes were produced.
Along with the steady growth of the company, Croma started to research and develop its own products. In the year 2002, it produced the first viscoelastics for the treatment of arthrosis. Further segments were then developed. After founding the first branches abroad in 2007, the Swiss company Xcelens® was acquired. Shortly thereafter, Croma took over the French manufacturer Cornéal® . These investments helped Croma to expand its international product portfolio in the ophthalmological segment significantly. The portfolio was also expanded by the dermatological aesthetics segment. The brand Princess® was successfully established. These hyaluronic acid syringes were used for minimally invasive beauty treatments. This was an international trend, recognized early on, which developed into the core business over the following years. Together with Bausch & Lomb, Croma distributed the innovative, non-steroidal anti-inflammatory agent Yellox® . As the years went by, Yellox® became an international bestseller. As part of a comprehensive strategic re-orientation, the focus was placed on minimally invasive aesthetic treatments. Croma sold its product portfolio in the segments of ophthalmology and orthopaedics to Valeant Pharmaceuticals. Croma continues to operate as a producer of hyaluronic acid within these segments.
The new headquarters accommodate one of the most modern automated manufacturing line in the world.
With around 450 employees and 12 subsidiaries in Brazil, the European Union and Switzerland, Croma is one of the most successful pharmaceutical companies in Austria.
Research & Development
Our own Research and Development team is focused on fundamental research and product development supported by Croma’s internal clinical development department.
A second research centre in Tulln (Austria) is used as a biotech incubator for the development and synthesis of novel polymers.
Croma invests almost 30 percent of its annual turnover in the research and development of medical devices, pharmaceuticals and cosmetics.
In addition, Croma maintains numerous cooperations with national and international research institutes.
The in-house research labs offer numerous advantages: They enable permanent quality assurance in the development of safe and effective products as well as therapies.
The competences of Croma are so broad that the entire product life cycle is covered. The repertoire of Croma includes evaluation of product safety, efficacy and medical benefits. It includes the generation of clinical data for the successful development, registration and commercialization of the products.
Social Responsibility
'Giving back eyesight, giving back hope'
As a pharmaceutical company we are well aware of our social responsibilities. Croma-Pharma is committed to sharing knowledge and experience/expertise to improve health standards especially in underdeveloped regions of the world. For many years Croma-Pharma has been supporting the internationally-active relief agency LIGHT FOR THE WORLD with much needed ophthalmic products and expertise and manpower.
Large quantities of pharmaceuticals, viscoelastic fluids and intraocular lenses from own production, which are desperately needed in Africa for cataract surgeries – have been sponsored to LIGHT FOR THE WORLD as in-kind donations. The long-time partnership with LIGHT FOR THE WORLD has been awarded with the TRIGOS, the most important CSR award in 2014.